Clinuvel Pharmaceuticals Limited Stock Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
02:04:22 04/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 5.275 EUR | -0.47% |
|
-13.00% | -27.91% |
| 08-28 | Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10 | MT |
| 08-28 | Clinuvel Pharmaceuticals Limited, 2026 Earnings Call, Aug 27, 2026 |
| Market Cap | 417M 300M 258M 242M 221M 413M 28.33B 2.86B 1.11B 14.48B 1.13B 1.1B 46.63B | P/E 2027 * |
11.6x | P/E 2028 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 133M 95.44M 82.12M 77.06M 70.51M 132M 9.02B 912M 355M 4.61B 358M 351M 14.85B | EV / Sales 2027 * |
1.4x | EV / Sales 2028 * | 0.96x |
| Free-Float |
83.79% | Yield 2027 * |
0.66% | Yield 2028 * | 0.79% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CUV | Delayed | |
Tradegate
| UR9 | Real-time | |
|
Boerse Muenchen
| UR9 | Real-time | |
|
Deutsche Boerse AG
| UR9 | Delayed | |
|
OTC Markets
| CLVLF | Delayed | |
|
Berne S.E.
| UR9 | End-of-day quote | |
|
Börse Stuttgart
| UR9 | Delayed |
Last Transcript : Clinuvel Pharmaceuticals Limited
| 1 day | -0.47% | ||
| 1 week | -13.00% | ||
| Current month | -0.08% | ||
| 1 month | -4.79% | ||
| 3 months | -4.79% | ||
| 6 months | -12.85% | ||
| Current year | -27.91% |
| 1 week | 4.9 |  | 5.3 |
| 1 month | 4.9 | | 6.7 |
| Current year | 4.9 | | 7.39 |
| 1 year | 4.9 | | 7.45 |
| 3 years | 4.8 | | 10.98 |
| 5 years | 4.8 | | 27 |
| 10 years | 3.33 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.47% | -13.00% | - | - | 302M | |
| -1.32% | +4.31% | +49.43% | +2.38% | 85.08B | |
| -3.77% | +0.79% | +498.34% | +31.58% | 60.21B | |
| +0.95% | +1.77% | -15.77% | -34.78% | 59.71B | |
| -1.60% | -7.63% | -3.65% | +31.05% | 51.1B | |
| +0.09% | -0.54% | +9.26% | +170.07% | 48.73B | |
| +0.68% | +1.24% | +58.35% | -15.79% | 32.9B | |
| -0.36% | +0.60% | +47.78% | +103.08% | 26.11B | |
| +0.79% | -6.56% | -2.56% | +192.31% | 22.6B | |
| +1.10% | -1.67% | +64.17% | +113.16% | 16.42B | |
| Average | -0.38% | -1.40% | +78.37% | +65.90% | 44.76B | |
| Weighted average by Cap. | -0.75% | -0.78% | +93.57% | +45.37% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.86M 68.26M 58.73M 55.12M 50.43M 94.12M 6.45B 652M 254M 3.3B 256M 251M 10.62B | 103M 74.14M 63.79M 59.86M 54.77M 102M 7.01B 708M 276M 3.58B 278M 272M 11.53B |
| Net income | 36.02M 25.92M 22.3M 20.93M 19.15M 35.73M 2.45B 248M 96.4M 1.25B 97.32M 95.2M 4.03B | 38.1M 27.42M 23.59M 22.14M 20.25M 37.8M 2.59B 262M 102M 1.32B 103M 101M 4.27B |
| Net Debt | -284M -204M -176M -165M -151M -282M -19.31B -1.95B -760M -9.87B -767M -750M -31.78B | -317M -228M -196M -184M -169M -315M -21.58B -2.18B -849M -11.03B -857M -839M -35.52B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/09/26 | €5.046 | -4.79% | 256 |
| 02/09/26 | €5.300 | +4.95% | 86 |
| 01/09/26 | €5.050 | 0.00% | 0 |
| 31/08/26 | €5.050 | -4.72% | 1,500 |
| 28/08/26 | €5.300 | -8.62% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
